论文部分内容阅读
目的对比两种治疗晚期非小细胞肺癌方案的长期疗效。方法将48例患者随机分为两组,治疗组26例采用吉西他滨1000mg/m2于治疗开始第1天、第8天静脉滴注,并同时给予顺铂70mg/m2于治疗开始第1天静脉滴注。对照组采用长春瑞滨(VP16)100mg于治疗开始第1天、第5天静脉滴注,并同时给予顺铂70 mg/m2于治疗开始第1天静脉滴注。两组治疗21天为1周期,其余治疗相同。观察对比两组患者的生存质量、生存时间、肿瘤缓解率。结果治疗组其生存质量有所增加,生存时间明显延长,治疗总有效率有所增加,与对照组比较差异有显著性(P<0.01或0.05)。结论吉西他滨联合顺铂治疗未全身转移的晚期非小细胞肺癌具有良好的长期效果,是联合化疗晚期非小细胞肺癌的较佳方案。
Objective To compare the long-term effects of two treatments for advanced non-small cell lung cancer. Methods 48 patients were randomly divided into two groups. 26 cases in the treatment group received intravenous infusion of gemcitabine 1000mg / m2 on the first day and the eighth day after the start of treatment and 70mg / m2 of cisplatin on the first day of treatment Note. The control group received vinorelbine (VP16) 100mg on the first day of treatment, intravenous drip on the fifth day and cisplatin 70 mg / m2 on the first day of treatment. Two groups of 21 days for the treatment of 1 cycle, the remaining treatment the same. The quality of life, survival time and tumor response rate were compared between the two groups. Results The quality of life of the treatment group increased, the survival time was significantly prolonged, the total effective rate increased, compared with the control group, the difference was significant (P <0.01 or 0.05). Conclusion The combination of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer without systemic metastasis has a good long-term effect and is a preferable combination chemotherapy combined with chemotherapy for advanced non-small cell lung cancer.